Cargando…
Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies
BACKGROUND: Mesothelin is expressed at very low levels by normal mesothelial cells but is overexpressed in several human cancers. This makes mesothelin a promising target for immunotherapy. Limited data exist about mesothelin expression in esophageal carcinoma. In a current clinical trial, the highl...
Autores principales: | Moentenich, Valeska, Comut, Erdem, Gebauer, Florian, Tuchscherer, Armin, Bruns, Christiane, Schroeder, Wolfgang, Buettner, Reinhard, Alakus, Hakan, Loeser, Heike, Zander, Thomas, Quaas, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249595/ https://www.ncbi.nlm.nih.gov/pubmed/32547645 http://dx.doi.org/10.1177/1758835920917571 |
Ejemplares similares
-
Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020) -
Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020) -
PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis
por: Essakly, Ahlem, et al.
Publicado: (2019) -
Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018) -
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2019)